Nymox Pharmaceutical Corp
NYMX
NYMX was delisted on the 6th of July, 2023.
46 hedge funds and large institutions have $12.3M invested in Nymox Pharmaceutical Corp in 2018 Q3 according to their latest regulatory filings, with 1 funds opening new positions, 18 increasing their positions, 12 reducing their positions, and 4 closing their positions.
50% more repeat investments, than reductions
Existing positions increased: 18 | Existing positions reduced: 12
6% less funds holding
Funds holding: 49 → 46 (-3)
26% less capital invested
Capital invested by funds: $16.5M → $12.3M (-$4.24M)
75% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 4
93% less call options, than puts
Call options by funds: $113K | Put options by funds: $1.71M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PPA
Parametric Portfolio Associates
Seattle,
Washington
|
+$257K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$232K |
| 3 |
Simplex Trading
Chicago,
Illinois
|
+$158K |
| 4 |
BlackRock
New York
|
+$47.5K |
| 5 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$36.3K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Bank of Montreal
Toronto,
Ontario, Canada
|
-$291K |
| 2 |
WS
Wedbush Securities
Los Angeles,
California
|
-$189K |
| 3 |
Brown Advisory
Baltimore,
Maryland
|
-$90K |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$53.9K |
| 5 |
AWM
AE Wealth Management
Topeka,
Kansas
|
-$34K |
NYMX Hedge Fund Activity: Q3 2018 in Review
46 of the 4,375 institutional investors tracked by Wall St. Rank reported a position in Nymox Pharmaceutical Corp (NYMX) for Q3 2018, worth a combined $12.3M — down 26% from $16.5M a quarter earlier.
Sellers outnumbered buyers: 4 funds closed out of NYMX and 1 opened new positions — a net loss of 3 holders — while 12 trimmed existing stakes and 18 added.
The largest buyer was Parametric Portfolio Associates, adding an estimated $257K. The largest seller was Bank of Montreal, cutting an estimated $291K.
- 46 institutional investors held Nymox Pharmaceutical Corp (NYMX) as of Q3 2018, down from 49 in Q2 2018.
- Funds reported $12.3M of Nymox Pharmaceutical Corp stock for Q3 2018, down 26% quarter-over-quarter.
- 1 fund opened new Nymox Pharmaceutical Corp positions in Q3 2018 and 4 closed out, a net change of -3 holders.
- The largest Nymox Pharmaceutical Corp buyer in Q3 2018 was Parametric Portfolio Associates, an estimated $257K added.
- The largest Nymox Pharmaceutical Corp seller in Q3 2018 was Bank of Montreal, an estimated $291K sold.
Based on aggregated 13F filings for Q3 2018.